Platinum OpinionAdjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
References (12)
- et al.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicenter, open-label, randomized, phase 3 trial
Lancet Oncol
(2021) - et al.
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
J Urol
(2011) - et al.
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Ann Oncol.
(2020) - et al.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicenter, randomized, placebo-controlled phase 3 trial
Lancet
(2020) - et al.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Lancet Oncol
(2017) - et al.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet
(2017)
There are more references available in the full text version of this article.
Cited by (8)
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
2023, European UrologySLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma
2023, iScienceCitation Excerpt :Moreover, patients with high SLC17A9 levels showed higher macrophage regulation scores, lymphocyte infiltration signature scores, TGF-beta response scores, Th1 cell scores, and Th2 cell scores, thereby highlighting the complex effects of SLC17A9 on the immune microenvironment. Immune checkpoint inhibitors have been extensively studied and applied to the clinical treatment of several cancers.36,37,38 This study observed that 12 common immune checkpoint molecules,39 represented by PD1, CTLA4, and LAG3, were highly expressed in the SLC17A9 high-expression group.
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer
2023, Cellular and Molecular Biology LettersClinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer
2023, Journal of Clinical Medicine
© 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.